Ph I Ipilimumab Vemurafenib Combo

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: July 21, 2011
Last updated: January 23, 2014
Last verified: January 2014

July 21, 2011
January 23, 2014
November 2011
April 2013   (final data collection date for primary outcome measure)
Phase I: Safety and tolerability of combination of Ipilimumab and Vemurafenib as determined by the number and grade of Adverse Event (AEs)/Serious Adverse Events (SAEs) [ Time Frame: During dose escalation and for up to 12 weeks following the treatment of the last subject in Phase 1 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01400451 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Ph I Ipilimumab Vemurafenib Combo
A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma

Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and the Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) inhibitor mAb Ipilimumab will be safe and feasible and will show preliminary evidence of anti-tumor efficacy and survival in comparison to historical results following treatment with either agent alone.

Not Provided
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Drug: Ipilimumab (BMS-734016)
    Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
    Other Names:
    • Yervoy®
    • Ipilimumab
    • BMS-734016
  • Biological: Vemurafenib
    tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
Experimental: Ipilimumab + Vemurafenib
  • Drug: Ipilimumab (BMS-734016)
  • Biological: Vemurafenib

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
May 2014
April 2013   (final data collection date for primary outcome measure)

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Metastatic melanoma with activating V600 BRAF mutation
  • Measurable Tumor
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1

Exclusion Criteria:

  • Autoimmune disease
  • Active Brain Metastasis (must be stable after radiation for at least one month)
  • Prior therapy with immune stimulating agents
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
CA184-161, 2011-000906-22
Bristol-Myers Squibb
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP